All In Biotech

Drug Trial Radar · NCT05358249

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

74

Actual

Start

Oct 24, 2022

Primary completion

Sep 28, 2026

Study completion Sep 28, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Conditions

  • KRAS G12C Mutant Solid Tumors
  • Carcinoma, Non-Small Cell Lung
  • Carcinoma, Non-Small-Cell Lung
  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Carcinoma
  • Nonsmall Cell Lung Cancer
  • Colorectal Cancer
  • Colorectal Carcinoma
  • Colorectal Neoplasms
  • Colorectal Tumors
  • Neoplasms, Colorectal

Interventions

  • JDQ443Drug

    KRAS G12C inhibitor, oral

  • trametinibDrug

    MEK inhibitor, oral

  • RibociclibDrug

    CDK4/6 inhibitor, oral

  • cetuximabBiological

    EGFR inhibitor, intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.Time frame: 28 days
  2. Dose escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatmentTime frame: 24 months
  3. Dose escalation: Frequency of dose interruptions and reductions, by treatmentTime frame: 24 months
  4. Dose Escalation: Dose intensity by treatmentTime frame: 24 months
  5. PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1Time frame: 24 months

Locations

13 sites in 8 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • NYU School of Medicine

    New York, New York

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, Seoul, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.